D
Do Young Kim
Researcher at Yonsei University
Publications - 737
Citations - 18320
Do Young Kim is an academic researcher from Yonsei University. The author has contributed to research in topics: Hepatocellular carcinoma & Medicine. The author has an hindex of 58, co-authored 674 publications receiving 15091 citations. Previous affiliations of Do Young Kim include University of Ulsan & Fred Hutchinson Cancer Research Center.
Papers
More filters
Proceedings ArticleDOI
Hot carrier dynamics, relaxation, and the effects of polaron formation in metal-halide perovskites
Shashi Sourabh,Vincent R. Whiteside,Brandon K. Durant,Rebecca Scheidt,Yaxin Zhai,Kang Xueliang Dehui Sun Dongzhou Wang,Do Young Kim,Matthew C. Beard,Ian R. Sellers +8 more
TL;DR: In this article , several perovskites are discussed that have been assessed via various experimental techniques to determine the effects of their composition, dimensionality, and structural stability on hot carriers and polaron formation.
Journal ArticleDOI
Strangulated small bowel obstruction following endoscopic retrograde cholangiopancreatography.
Do Young Kim,Yongjin Kim,Tae Yoon Lee,Chan Sup Shim,Hyun Ah Chung,In Sung Son,Young Koog Cheon +6 more
TL;DR: The following is the first report of intestinal obstruction following endoscopic retrograde cholangiopancreatography (ERCP) of an 81-year-old female, admitted for evaluation following an abnormal liver function test and abdominal ultrasound findings of a dilated common bile duct 12 mm in diameter.
Journal ArticleDOI
Drought-simulation facility for assessing tolerance and risks of genetically modified crops
Journal ArticleDOI
Predictors of Sarcopenia in an Obese Asian Population.
Min Je Sung,Jun Yong Park,Hye Won Lee,Beom Kyung Kim,Do Young Kim,Sang Hoon Ahn,Seung Up Kim +6 more
TL;DR: In this article, the prevalence of sarcopenia and its predictors in obese subjects was investigated and subjects who underweight were more likely to suffer from sarcopenias than those who overweight.
Journal ArticleDOI
Treatment with Ramucirumab-paclitaxel in a metastatic gastric cancer patient undergoing hemodialysis: A case report.
TL;DR: In this paper, Ramucirumab, a human Ig 1 monoclonal antibody against vascular endothelial growth factor receptor-2, in combination with paclitaxel is a second-line chemotherapy for patients with metastatic gastric cancer.